Glioblastoma is the most prevalent and aggressive primary brain tumor. Standard treatment of glioblastoma includes surgical resection followed by radiation, administration of temozolomide and tumor treating fields. Even with this therapeutic approach, tumor recurrence is inevitable mainly due to the presence of glioma stem cells (GSCs), which are characterized by high migratory potential, resistance to chemotherapy and radiation and the ability to form recurrent tumors. GSCs exhibit remarkable plasticity and dynamically transition between more differentiated and less differentiated states via mechanisms akin to cellular reprogramming. These mechanisms of GSC plasticity have led to examination of factors that might influence tumor propagating potential and tumor recurrence.
Within the dynamic intratumoral niche, GSCs demonstrate a high degree of cellular plasticity, reversibly interconverting between stem-like states and more differentiated states as a result of environmental cues/signaling fluctuations. Such plastic adaptive properties are mostly driven by multiple dynamic, reversible epigenetic modifications. In this Research Topic, we will discuss the concept of cellular plasticity, introduce dynamic epigenetic and epitranscriptomic mechanisms as potential key regulators of GSC plasticity, and finally propose epigenetic based therapeutics as a mean of attenuating glioblastoma plasticity to improve patient outcome.
We invite authors to submit high-quality Review and Original Research articles. Some of the themes we would like to address with this Research Topic are:
-Epigenetic heterogeneity in glioblastoma
-Transcriptional heterogeneity in glioblastoma
-Glioma stem cell phenotypic plasticity
-Epitranscriptome in GSCs
-Single cell transcriptomics and epigenetics in glioblastoma
-Epigenetic based therapeutics
-GSC targeting therapies
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Glioblastoma is the most prevalent and aggressive primary brain tumor. Standard treatment of glioblastoma includes surgical resection followed by radiation, administration of temozolomide and tumor treating fields. Even with this therapeutic approach, tumor recurrence is inevitable mainly due to the presence of glioma stem cells (GSCs), which are characterized by high migratory potential, resistance to chemotherapy and radiation and the ability to form recurrent tumors. GSCs exhibit remarkable plasticity and dynamically transition between more differentiated and less differentiated states via mechanisms akin to cellular reprogramming. These mechanisms of GSC plasticity have led to examination of factors that might influence tumor propagating potential and tumor recurrence.
Within the dynamic intratumoral niche, GSCs demonstrate a high degree of cellular plasticity, reversibly interconverting between stem-like states and more differentiated states as a result of environmental cues/signaling fluctuations. Such plastic adaptive properties are mostly driven by multiple dynamic, reversible epigenetic modifications. In this Research Topic, we will discuss the concept of cellular plasticity, introduce dynamic epigenetic and epitranscriptomic mechanisms as potential key regulators of GSC plasticity, and finally propose epigenetic based therapeutics as a mean of attenuating glioblastoma plasticity to improve patient outcome.
We invite authors to submit high-quality Review and Original Research articles. Some of the themes we would like to address with this Research Topic are:
-Epigenetic heterogeneity in glioblastoma
-Transcriptional heterogeneity in glioblastoma
-Glioma stem cell phenotypic plasticity
-Epitranscriptome in GSCs
-Single cell transcriptomics and epigenetics in glioblastoma
-Epigenetic based therapeutics
-GSC targeting therapies
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
